OEIS National Registry: What's Been Done? What's Next?

Bob Tahara MD FACS FSVS RVT RPVI
Director,Allegheny Vein & Vascular,Bradford PA
Adjunct Assistant Professor of Surgery, Department of Surgery/Division Vascular Surgery, University of Pittsburgh School of Medicine

@7th OEIS Annual Meeting (Virtual) Orlando, FL
25 SEPT 2020

ALLEGHENY VEIN & VASCULAR

Disclosures

- Technical Director for OEIS National Registry
- Chair, OEIS National Registry Committee

Editorial Disclosures

Atypical talk for me: Does not involve vascular technical innovation, ultrasound, tibial access or limb salvage.

Brett Wiechmann Disclosures

- I do not do chin or butt lifts contrary to Bret's intro

ALLEGHENY VEIN & VASCULAR

Overview

- Background & current status of OEIS National Registry
- Current Reporting Dashboards
- Cardiac Module Development
  - outline and process
  - Anticipated timeline

ALLEGHENY VEIN & VASCULAR

What's Been Done?

- Vendor=> Syntactx, NYC
- Dr. Jeff Carr driving force for OEIS
- Early 2017- V1
- Spring of 2018 – V2
  - Changed the underlying data structure
  - Introduced new capabilities in analytics
  - Modified (I hesitate to say "improved") the web based EDC

ALLEGHENY VEIN & VASCULAR

What's Been Done?

- November 2017- Lauren Jones MS added as Registry Manager
- April 2018 – Dr. Bob Tahara joins as Technical Director (AKA Lead Masochist)
- May 2018 became apparent basic architecture of the database/EDC including its structure(s) and relations needed significant overhaul
- May-November 2018 "6 months of hell"

ALLEGHENY
VEIN & VASCULAR

WHISKY

What's Been Done?

- OEIS NR is a QCDR- Qualifed Clinical Data Registry which allows us to support:
  - Reporting Quality Measures (QMs) for participating physicians/sites (based on NPI/TIN combination)
  - Reporting Improvement Activities (IAs) for participating physicians/sites (based on NPI/TIN combination)
  - 2020 remains essentially same as 2019 MIPS score: QMs 45% + IAs 15% = 60%

If you re-weight this may be up to 85%

ALLEGHENY VEIN & VASCULAR

What's Been Done?

- Publications
  - 1st peer reviewed paper from Registry published in JEVT this summer
  - 2nd paper (Safety and Efficacy) is being written as we speak
  - Research Committee in charge of publication strategy and map->we need ***INVOLVED*** volunteers

ALLEGHENY VEIN & VASCULAR

What's Been Done?

- November 2018-February 2018 technical formatting/validation/data transformation and finally the actual migration to the new V3 interface and data structure performed
- Now have all V1 and V2 data merged into the new format and EDC
- Analytics are now "in-house"
- QM query writing and analysis now "in-house"
- Actual reporting/transmittal is by Syntactx

ALLEGHENY VEIN & VASCULAR

Current Status

- Enhanced dashboards have been available over a year and are expanding
- Opportunities for clinical research and data mining from the Registry as a whole –and-
- Ability to do custom analytics for individual or aggregated sites on a per/hour added fee basis

ALLEGHENY
VEIN & VASCULAR



ALLEGHENY
VEIN & VASCULAR

OEIS National Registry Summary

Date 7/2/1948 1/21/2048

14685
Total Subjects

21694
Total Procedures

1.821%
Overall Complication Rate































OUTPATIENT ENDOVASCULAR AND INTERVENTIONAL SOCIETY

ALLEGHENY VEIN & VASCULAR



ALLEGHENY VEIN & VASCULAR

OEIS National Registry Summary

Date
7/2/1948 1/21/2048

21.69K
Total Procedures

33.68K
Total Lesions











9/24/2020 4:51:38 AM
Refresh Timestamp (UTC)

OEIS
OUTPATIENT ENDOVASCULAR AND INTERVENTIONAL SOCIETY

ALLEGHENY VEIN & VASCULAR

Back to report

TREATMENT MODALITY BY PROCEDURE INDICATION (PROCEDURE LEVEL)

Ath_Use	Atherectomy		Balloon/Stent		**Total**	
Procedure_Indication	ProcCount	%	ProcCount	%	**ProcCount**	**%**
Acute Limb Ischemia	1124	67.47%	1501	90.10%	**1666**	
Blank	315	34.92%	571	63.30%	**902**	
Claudication	7144	57.62%	11063	89.23%	**12398**	
Distal Embolization	14	87.50%	16	100.00%	**16**	
Maintenance of Patency	637	61.19%	958	92.03%	**1041**	
Major Tissue Loss	318	65.03%	429	87.73%	**489**	
Minor Tissue Loss (Ulceration)	2512	63.15%	3548	89.19%	**3978**	
Other	200	28.94%	648	93.78%	**691**	
Prevention of Aneurysm Complication	3	18.75%	11	68.75%	**16**	
Rest Pain (CLI)	1722	60.19%	2593	90.63%	**2861**	
Treatment of Symptomatic Aneurysm	1	14.29%	7	100.00%	**7**	
Total	**11961**	**55.14%**	**18721**	**86.30%**	**21694**	

ALLEGHENY
VEIN & VASCULAR

THE DIRECTORS CUT
(THE GOOD, THE BAD AND THE UGLY)

What's Next?

- We need volunteers who are willing and able to assist with QM development
- Bringing the Cardiac Module online and into production
- Maintenance of our QCDR functions
- Further publications

ALLEGHENY
VEIN & VASCULAR

What's Next?

- We need volunteers who are willing and able to assist with QM development
- Bringing the Cardiac Module online and into production
- Maintenance of our QCDR functions
- Further publications

ALLEGHENY
VEIN & VASCULAR

What's Next-Cardiac Module?

- Cardiac Module Development
  - Coronary (Diagnostic and Interventions)
  - Rhythm Management/EP
  - (future possible- Structural Heart)
- "Bolt on" to current architecture but requires completely new data fields and variables to account for the above interventions
- Maintains Demographics, Clinical status, Access tabs in current web EDC

ALLEGHENY VEIN & VASCULAR

What's Next- Cardiac Module?

- Funding: grants have already been obtained and are under progress to completely fund
- Hiring an additional FTE employee to assist with development as well as continuing operations
- Selecting and empaneling cardiac experts to assist with data field and variable development
- Design and construction of new EDC webpages
- Design and construction of reporting dashboards

ALLEGHENY VEIN & VASCULAR

What's Next- Cardiac Module?

- Schedule is currently behind about 7 months from original timeline developed in 10/2019
  - Covid
  - Covid related industry delays
- Anticipate actual design and live meetings to settle data fields and variables will begin 11/2020
- Anticipate beta product by 3/2021
- Production product rollout depends on above

ALLEGHENY VEIN & VASCULAR

Summary

- Incredible development and improvement of PAD module from ground up over 2017-2018
- Robust data collection and analytics yielding results over 2019 and into 2020
- Publications are now real from this data
- Cardiac module is coming. (as is winter!)

ALLEGHENY
VEIN & VASCULAR

Questions? Comments?

Feel free to call, email, or send carrier pigeon

Bob Tahara MD FACS FSVS RVT RPVI

Director

Allegheny Vein & Vascular

Bradford PA

(814) 368-8490

kodb2105@icloud.com

ALLEGHENY VEIN & VASCULAR